MWAI on OTC

MedWellAI, Inc.

American finance services company, incorporated in Nevada, listed on OTC (MWAI)1

In its 2026 annual report the company says: “We are a publicly traded company (OTCQB: MWAI), based in Clearwater, Florida, that is focused on earning commissions through the use of a fully automated e-commerce platform that connects in-office buyers with multiple FDA-registered 503B pharmacies, offering GLP-1 weight management therapies, peptides and other compounds.”4

Price unavailable

Last updated Oct 21, 2026.

Overview

$527.9KRevenue, fiscal 20262
-$1.6MNet income, fiscal 20262

Compare with Solana Co, Aurelion Inc. or I-ON Digital Corp., or pick any stock.

  • TickerMWAI on OTC1
  • IndustryFinance Services1
  • HeadquartersClearwater, Florida1
  • Incorporated inNV3
  • Business address2380 Drew Street, Suite 3, Clearwater, Fl 337653
  • Filer categoryNon-accelerated filer, Smaller reporting company3

We were incorporated in the State of Nevada on March 22, 2011 under the name Lightcollar, Inc. In March 2015, we changed our name to EMS Find, Inc. On May 30, 2017, Integrated Ventures, Inc. (“Integrated Ventures”), a Nevada corporation, was formed as a wholly owned subsidiary of the Company. Pursuant to an Agreement and Plan of Merger dated May 30, 2017, Integrated Ventures was merged into the Company, with the Company being the surviving corporation and changing its name to Integrated Ventures, Inc. In July 2024, the Company formed three wholly-owned subsidiaries, MedWell Direct, LLC (“MedWell Direct”), MedWell Facilities, LLC (“MedWell Facilities”), and MedWell USA, LLC (“MedWell USA), all of which were organized in the State of Nevada. In June 2025, we changed our name to MedWellAI, Inc.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-234.2%Operating margin2
-301.1%Net margin2
-11.2%Revenue growth, 20262
-$307.0KFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Other costs90¢$475.5K
  • Interest10¢$52.3K

Out of $527.9K in revenue.2 The company lost money this year.

Financial statements

Revenue56789102$527.9K in 2026+89% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $279.1K$279.1K20192020: $454.2K$454.2K2020+63%2021: $1.9M$1.9M2021+308%2022: $6.6M$6.6M2022+254%2023: $3.9M$3.9M2023−41%2024: $0$020242025: $594.8K$594.8K20252026: $527.9K$527.9K2026−11%
Gross profit5678-$2.4M in 2023+235% since 2019
-$4.0M-$2.0M0$2.0M$4.0M2019: -$726.3K-$726.3K20192020: -$542.2K-$542.2K2020−25%2021: $931.0K$931.0K20212022: $2.7M$2.7M2022+188%2023: -$2.4M-$2.4M2023
Operating income56789102-$1.2M in 2026−73% since 2019
-$30.0M-$20.0M-$10.0M02019: -$4.6M-$4.6M20192020: -$1.0M-$1.0M2020−78%2021: -$21.7M-$21.7M2021+2036%2022: -$688.0K-$688.0K2022−97%2023: -$25.2M-$25.2M2023+3559%2024: -$9.1M-$9.1M2024−64%2025: -$2.8M-$2.8M2025−69%2026: -$1.2M-$1.2M2026−56%
Net income56789102-$1.6M in 2026−83% since 2019
-$30.0M-$20.0M-$10.0M02019: -$9.5M-$9.5M20192020: -$1.1M-$1.1M2020−89%2021: -$22.4M-$22.4M2021+1974%2022: -$565.5K-$565.5K2022−97%2023: -$25.5M-$25.5M2023+4402%2024: -$11.5M-$11.5M2024−55%2025: -$3.6M-$3.6M2025−69%2026: -$1.6M-$1.6M2026−56%
Fiscal year20192020202120222023202420252026
Revenue$279.1K5$454.2K6$1.9M7$6.6M8$3.9M9$010$594.8K2$527.9K2
Cost of revenue$1.0M5$996.4K6$920.4K7$3.9M8$2.7M9$3.9M9
Gross profit-$726.3K5-$542.2K6$931.0K7$2.7M8-$2.4M8
Research and development
Operating expenses$3.4M8$22.7M8
Operating income-$4.6M5-$1.0M6-$21.7M7-$688.0K8-$25.2M9-$9.1M10-$2.8M2-$1.2M2
Interest$214.4K5$655.2K6$436.0K7$18.3K8$276.9K9$83.0K10$52.2K10$52.3K2
Income before tax-$565.5K8-$25.5M9-$9.2M10-$2.9M2-$1.5M2
Income tax$05$06$07$08$09$010$02$02
Net income-$9.5M5-$1.1M6-$22.4M7-$565.5K8-$25.5M9-$11.5M10-$3.6M2-$1.6M2
Earnings per share-$0.167-$0.017-$11.989-$2.729
Earnings per share (diluted)-$11.989-$2.729
Shares (weighted, basic)204.7M shares72.2M shares94.4M shares9
Shares (weighted, diluted)2.2M shares94.4M shares9

Compare MedWellAI, Inc. with another company

Corporate structure

MedWellAI, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MedWellAI, Inc.

  • MedWellAI, Inc. Clearwater, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MedWellAI, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Furniture and fixtures$2.2K2 Jun 30, 2026$2.2K2 Jun 30, 20250%
Leasehold improvements$10.0K2 Jun 30, 2026$40.9K2 Jun 30, 2025−75.6%
Property and equipment, before depreciation$12.2K2 Jun 30, 2026$43.1K2 Jun 30, 2025−71.7%
Accumulated depreciation$11.3K2 Jun 30, 2026$1.1K2 Jun 30, 2025+970.9%
Property and equipment, net$8902 Jun 30, 2026$42.1K2 Jun 30, 2025−97.9%
Operating-lease assets (leased space)$02 Jun 30, 2026$95.5K2 Jun 30, 2025−100.0%

Real estate and locations

ItemLatestA year beforeChange
Area of land750 sq ft2 Jun 30, 2026750 sq ft10 Jun 30, 20250%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$670.0K2 Jun 30, 2026$4.2M15 Jun 30, 2018−83.9%
Intangible assets, net (excluding goodwill)$27.7K2 Jun 30, 2026$51.4K2 Jun 30, 2025−46.2%
Finite-lived intangibles, net$51.4K10 Jun 30, 2025$010 Jun 30, 2024

Properties, in its own words

Our corporate offices are located at 2380 Drew Street, Suite 3, Clearwater, Florida 33765. Our telephone number is (813) 384-8480.

Item 2 of the 10-K filed Oct 13, 2026.4

Leadership

Who has led MedWellAI, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steve Rubakh2016–now
20202025
Board members and other officers (3)

Former names

  • INTEGRATED VENTURES, INC.Aug 3, 2017 to May 16, 20253
  • EMS FIND, INC.Mar 26, 2015 to Jul 21, 20173
  • LIGHTCOLLAR, INC.Jun 7, 2011 to Mar 20, 20153

Timeline

  1. Apr 17, 20268-K Bylaws or fiscal year changed19
  2. Aug 7, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events20
  3. Jun 24, 20258-K Bylaws or fiscal year changed; Other events21
  4. Nov 20, 20248-K Executive or director change22
  5. Sep 3, 20248-K Entered a material agreement; Completed an acquisition or sale23
  6. Apr 21, 20238-K Bylaws or fiscal year changed; Other events24
  7. Sep 16, 20228-K Entered a material agreement25
  8. Jul 6, 20228-K Entered a material agreement; Other events26
  9. Apr 29, 2016New chief executive Steve Rubakh becomes CEO16

Filings

49 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 8 major events, 2 insider forms, 2 large holders, 16 other. The latest 20:

  1. Oct 13, 202610-K EDGAR
  2. Sep 28, 2026NT 10-K EDGAR
  3. Jun 18, 20265 EDGAR
  4. May 5, 202610-Q EDGAR
  5. Apr 17, 20268-K EDGAR
  6. Feb 23, 202610-Q EDGAR
  7. Feb 18, 2026NT 10-Q EDGAR
  8. Nov 14, 202510-Q EDGAR
  9. Sep 30, 202510-K EDGAR
  10. Sep 30, 2025NT 10-K EDGAR
  11. Aug 7, 20258-K EDGAR
  12. Jun 24, 20258-K EDGAR
  13. May 16, 202510-Q EDGAR
  14. May 15, 2025NT 10-Q EDGAR
  15. Feb 14, 202510-Q EDGAR
  16. Feb 14, 2025UPLOAD EDGAR
  17. Feb 13, 2025CORRESP EDGAR
  18. Nov 20, 2024S-8 EDGAR
  19. Nov 20, 20248-K EDGAR
  20. Nov 15, 202410-Q EDGAR

The 49 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2025Rubakh SteveCEOBuy461,250$0.61$281.4KForm 4
Aug 28, 2023Rubakh SteveCEOBuy10,000$1.61$16.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How MedWellAI, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMedWellAI, Inc.1
  • CIK0001520118
  • Employer ID (EIN)82-17253854
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inNevada4
  • Fiscal year endsJune 301
  • Industry code (SIC)6199 Finance Services1
  • SEC reviewing officeOffice of Crypto Assets, Division of Corporation Finance1
  • Business address2380 Drew Street, Suite 3, Clearwater, FL 337651
  • Phone813-358-44001
  • Shares outstanding6,536,580 shares as of Oct 7, 20264
  • Public float$1.6M as of Dec 31, 20254
  • AuditorM&K CPAS, PLLC, Woodlands, TX PCAOB ID 27384
  • On EDGAR sinceJun 7, 20111
  • Filings226 in all: 8-K (53), 10-Q (44), 10-K (15), CORRESP (10), UPLOAD (10), 4 (9), 8-K/A (8), NT 10-Q (8)1
    All 34 form types

    NT 10-K (7), S-1/A (7), 5 (5), DEF 14C (5), SC 13G (5), EFFECT (4), PRE 14C (4), SC 13G/A (4), 10-Q/A (3), POS AM (3), 10-K/A (2), 144 (2), 3 (2), S-1 (2), S-3 (2), S-3/A (2), 10-KT (1), 424B3 (1), 424B5 (1), 424B8 (1), 5/A (1), 8-A12G (1), NT 10-Q/A (1), RW (1), S-8 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Oct 13, 2026
    Quarterly report (10-Q) May 5, 2026
    Latest 8-K (8-K) Apr 17, 2026

Risk factors and legal proceedings

The risks MedWellAI, Inc. names in Item 1A of its 10-K filed Oct 13, 2026: 20 risks under these headings, as written.4

  • Risks Related to Our Business
  • Because we are an early-stage company with minimal revenue and a history of losses and we expect to continue to incur substantial losses for the foreseeable future, we cannot assure you that we can or will be able to operate profitably.
  • Changes in FDA regulation of compounded pharmaceuticals could adversely affect our supply of GLP-1 medications and harm our business.
  • Our use of artificial intelligence (AI) or other emerging technologies could adversely impact our business and financial results.
  • Natural disasters and geo-political events could adversely affect our business.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights.
  • We are increasingly dependent on information technology systems and infrastructure (cyber security).
  • If we are unable to attract, train and retain technical and financial personnel, our business may be materially and adversely affected.
  • We depend heavily on our chief executive officer, and his departure could harm our business.
  • Our auditors’ report includes a going concern paragraph.
  • We may not be able to respond quickly enough to changes in technology and technological risks, and to develop our intellectual property into commercially viable products.
  • Risks Related to Our Securities
The other 10 risks
  • Our lack of internal controls over financial reporting may affect the market for and price of our common stock.
  • Our common stock is deemed to be “penny stock,” which may make it more difficult for investors to sell their shares due to disclosure and suitability requirements.
  • FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our stock.
  • The market price for our common stock may be volatile and your investment in our common stock could suffer a decline in value.
  • Raising funds by issuing equity or convertible debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital.
  • We may issue preferred stock whose terms could adversely affect the voting power or value of our common stock.
  • Because certain existing stockholders own a large percentage of our voting stock, other stockholders’ voting power may be limited.
  • We do not have a majority of independent directors on our board and the company has not voluntarily implemented various corporate governance measures, in the absence of which stockholders may have more limited protections against interested director transactions, conflicts of interest and similar matters.
  • Our share price is volatile and may be influenced by numerous factors that are beyond our control.
  • We have no current plans to pay dividends on our common stock and investors must look solely to stock appreciation for a return on their investment in us.

Legal proceedings

We are not aware of any pending legal proceedings in which we are a party or in which any of our directors, officers or affiliates, any owner of record or beneficiary of more than 5% of any class of our voting securities is a party adverse to us or has a material interest adverse to us.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28